“A Threat to NJ and Del.’s Primacy as Top Venues for Hatch-Waxman Matters?” New Jersey Law Journal, December 5, 2016.

The Districts of New Jersey and Delaware are recognized as the primary venues for Hatch-Waxman or ANDA (Abbreviated New Drug Application) litigation. But these preferred venues could be in jeopardy in light of the U.S. Supreme Court’s review of the Federal Circuit’s decision in Acorda Therapeutics v. Mylan Pharmaceuticals, writes Maegan Fuller.